A previous article examined King's Income Statement for the June quarter in some detail. Reported GAAP earnings were $0.02 less than the $0.09 per share we had forecast.
We have now updated the various financial metrics we use to analyze Cash Management, Growth, Profitability and Value. This post reports on the metrics for King Pharmaceuticals and the associated financial gauge scores. The metrics were calculated using data from King's current and historical financial statements, including those in the latest 10-Q report.
Before getting into the details, we will take a step back to introduce the subject of today's analysis.
King Pharmaceuticals, headquartered in Bristol, TN, manufactures and sells various brand-name prescription pharmaceuticals and other products. The acquisition of Alpharma, in a $1.6 billion deal completed in December 2008, added new painkilling medicines and animal health products.
In an important January 2009 decision, two King patents related to the muscle relaxant Skelaxin® (metaxalone) were invalidated by a U.S. District Court. Skelaxin was one of the company's best-selling products at the time. Generic versions of Skelaxin became available in the April 2010, and sales of King's branded product tumbled.
Pain-killing medications with features that deter abuse may be King's best hope for the future. The company seems especially optimistic about EMBEDA®, which first became available commercially in September 2009. King reported prescription growth of 15 percent for Embeda, an opioid for management of moderate to severe pain under certain conditions, during the month of June 2010.
King is also developing Acurox® product with Acura Pharmaceuticals (NASDAQ: ACUR), Remoxy® with Pain Therapeutics, Inc. (NASDAQ: PTIE), and the ALO-02 oxycodone/naltrexone product started by Alpharma. King management expressed optimism that non-clinical data seen to date will support a Remoxy NDA resubmission by the end of this year.
Additional background information about King and the business environment in which it is currently operating can be found in the look-ahead.
Mergers and acquisitions, such as King's purchase of Alpharma, pose a challenge to us at GCFR because a major deal can lead to both temporary and longer term changes to the company's financial results. Comparisons with the past, a key element of our approach, can be misleading. Temporary changes include unusual revenue growth and large restructuring expenses. In addition, it's not unusual for one transaction to be followed by others, such as asset divestitures that don't conform to the new organization's priorities.
For these and other reasons, extra caution has to be taken when evaluating a company in the immediate aftermath of a merger or acquisition. It is often prudent to "let the dust settle" before drawing any far-reaching conclusions.
With this caveat in mind, King's latest quarterly results produced the following changes to the gauge scores:
- Cash Management: 13 of 25 (down from 15 in March)
- Growth: 9 of 25 (down from 15)
- Profitability: 8 of 25 (unchanged)
- Value: 7 of 25 (up from 0)
- Overall: 34 of 100 (up from 28)
The current and historical values for the financial metrics that determine the gauge scores are listed below, with some brief commentary. Readers are encouraged to verify these figures and calculate others as they see fit using the filings available at the SEC's web site and elsewhere.



